SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid community frustration over stagnant price action and debates surrounding the upcoming legislative clarity, which many investors view as the necessary catalyst for institutional adoption. Despite these headwinds, the community remains deeply divided, with some users aggressively accumulating on dips while others express exhaustion over persistent delays and perceived lack of momentum.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as investors debate the potential for a rebound, with supporters highlighting upcoming catalysts and the community pushing for renewed momentum to break key resistance levels. While many users focus on the speculative nature of the project and its meme-coin status, others are actively coordinating buy campaigns to regain previous market highs.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as investors digest the bank's latest earnings results and monitor Jamie Dimon's cautious outlook regarding rising global geopolitical tensions and complex risks. The stock is a primary focus for the community as they weigh institutional commentary on credit quality and interest rate guidance against broader macro uncertainty.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased community chatter driven by its recent quantum-security recognition and ongoing infrastructure developments. Investors are actively debating the token's long-term utility versus its extended price consolidation, with many focused on accumulating positions ahead of anticipated sector-wide shifts.

Axelar delivers secure interchain communication. That means dApp users can interact with any asset, any application, on any chain, with one click. You can think of it as Stripe for Web3. Developers interact with a simple API atop a permissionless network that routes messages and ensures network security via proof-of-stake consensus.  Axelar is a blockchain that connects blockchains. To do this securely, Axelar network uses proof-of-stake consensus. Network validators produce new blocks, participate in multiparty signing and vote on external chain states. Tokenholders stake the AXL token, delegating tokens to a validator’s staking pool and receiving rewards, minus the validator’s commission.  The AXL token is used for governance and to pay network transaction fees to validators and tokenholders. However, users of the Axelar network do not need to hold the token. Conversions into AXL tokens and destination-chain tokens are handled on the back end, so that users need only pay gas once, in the source-chain token.  Axelar network rewards are “inflationary” — they increase the total supply of AXL — but there is potential for supply to become deflationary based on the transaction fee mechanic described above.

Axelar

Axelar is capturing community attention following the launch of a new XRPL EVM sidechain integration, which investors view as a pivotal step in expanding the network's utility. While some holders express frustration over recent price volatility and token dilution concerns, many remain focused on the project's long-term interoperability potential and its role in connecting major blockchain ecosystems.

Brown & Brown, Inc. is an insurance agency, wholesale brokerage, insurance program and service organization. It engages in the provision of insurance brokerage services and casualty insurance underwriting services. It operates through the following segments: Retail, Specialty Distribution, and Other. The Retail segment offers insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers. The Specialty Distribution segment consists of programs, wholesale brokerage, and specialty businesses. The company was founded by J. Adrian Brown and Charles Covington Owen in 1939 and is headquartered in Daytona Beach, FL.

Brown & Brown, Inc.

Brown & Brown Inc

Brown & Brown is trending as investors weigh strong earnings and consistent revenue growth against recent share price volatility and broader insurance sector headwinds. The community is actively debating whether the stock's current valuation offers a compelling entry point or signals a fundamental shift in its long-term growth trajectory.

Perma-Pipe International Holdings, Inc. engages in the design, manufacture, and sale of specialty piping and leak detection systems. Its products include industrial and secondary containment piping systems for transporting chemicals, hazardous fluids and petroleum products, insulated and jacketed district heating and cooling piping systems for efficient energy distribution to multiple locations from central energy plants, and the coating and/or insulation of oil and gas gathering flow and long lines for oil or mineral transportation. The company was founded on October 12, 1993 and is headquartered in The Woodlands, TX.

Perma-Pipe International Holdings Inc

Perma-Pipe International Holdings is gaining traction as investors highlight its role in critical infrastructure projects, particularly involving AI-enabled data centers and energy expansion in the Middle East. The community is actively discussing the company's strong project awards and potential for upward rerating, with many focusing on long-term accumulation despite recent sector-wide volatility.

Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending as institutional investors and traders focus on the bank's accelerating transformation strategy and improved profitability metrics. Community sentiment is mixed between bullish momentum driven by recent price breakouts and skepticism regarding the sustainability of the current rally given the stock's parabolic extension.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is experiencing significant community buzz due to its role in the Base ecosystem as an infrastructure layer for autonomous AI agents, with supporters highlighting its expanding utility and revenue-generating features. While the stock has seen high volatility, traders remain focused on its long-term potential as a key player in the AI-decentralized finance intersection.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BridgeBio Pharma is currently trending as investors monitor recent institutional activity, including significant stake increases by major asset managers, alongside a favorable patent settlement for a key industry competitor that improves the long-term outlook for the company's heart disease drug. Community discussions are heavily focused on the stock's potential for an institutional-led rally, with market participants eagerly awaiting upcoming quarterly results and data readouts for its core pipeline assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates CalciMedica Reports 2025 Financial Results and Provides Clinical Updates PR Newswire LA JOLLA, Calif., March 3, 2026 Internal...

How Is The Market Feeling About CalciMedica Inc?

<ul class="summary-bullets"><li>According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;</li><li>There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.</li><li>Oppenheimer sees the stock as oversold on today's news and "significantly undervalued."</li></ul>CalciMedica (CALC) shares closed down 76% and edged further 4% lower after-hours on Wednesday after the company said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.<h2 class="st-heading-2">Rationale For Discontinuation</h2>The biopharmaceutical company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/calcimedica-announces-discontinuation-of-phase-2-kourage-trial-in-aki-following-independent-data-monitoring-committee-recommendation-302671925.html">said</a> that the discontinuation decision followed a recommendation from an independent data monitoring committee that identified a safety concern.According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.CalciMedica will now perform a review of the clinical data, which will inform how evaluation of Auxora will proceed in acute kidney injuries. &nbsp;"Based on the IDMC's feedback, we will review the unblinded KOURAGE data and explore modifications to the trial design, particularly patient enrollment criteria, that may support further clinical testing of Auxora in patients with AKI," said CEO Rachel Leheny.CalciMedica is also evaluating Auxora in acute pancreatitis and severe COVID-19 pneumonia.<h2 class="st-heading-2">Analyst Take</h2>Oppenheimer on Wednesday said that shares of CALC were oversold after the company announced the discontinuation of the mid-stage trial in patients with kidney injury.Oppenheimer said that it caught up with management following the news, who said the safety concern identified by the independent committee's review of unblinded data "appears to stem not from the drug itself, but from aspects of this particular trial."The firm sees the stock as oversold on today's news and "significantly undervalued." Even if one removes any revenue potential in AKI from projections, Auxora's derisked $200M opportunity in acute pancreatitis alone supports a favorable outlook, the analyst said.The firm has an ‘Outperform’ rating on CalciMedica shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CALC stock jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user voiced hopes for a rebound in share price to sell.<stembedurl>https://www.stocktwits.com/tragusa/message/643195813</stembedurl>Another echoed Oppenheimer and said that the stock is oversold for the news. “This should correct itself either fast or slow but it will correct itself,” they said.<stembedurl>https://www.stocktwits.com/Lay1a/message/643185864</stembedurl><a href="https://stocktwits.com/symbol/CALC">CALC stock</a> has dropped 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q4-2025-earnings/cmyg0wMR40q">Tesla Shares Rise After Hours As EV Giant Commits To Vehicle Autonomy, AI With Cybercab And $2B xAI Investment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

CALC Stock Slumped 76% On Wednesday — Here’s Why

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 

Equity

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 


CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded CalciMedica to a "sell" rating in a report on Saturday...

CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?

CalciMedica (NASDAQ:CALC) Stock Price Down 2.1% - Time to Sell...

Stonepine Capital Management LLC Has $136,000 Stock Position in CalciMedica Inc. $CALC

Stonepine Capital Management LLC lowered its stake in shares of CalciMedica Inc. (NASDAQ:CALC - Free Report) by 76.9% during the second quarter, according to the company in its most recent filing...

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates...

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension CalciMedica Announces Publication in...

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora CalciMedica and Telperian Announce Collaboration to...

CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

CALC
CalciMedica Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CALC News

CALCCalciMedica Inc